Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06574698 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.
Trial Details
NCT Number NCT06574698
Lead Sponsor Guangzhou Women and Children's Medical Center
Conditions
(from sponsor)		 Neuroblastoma, GD2 Antibody (Naxitamab)
Related terms Neuroblastoma
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov